Maria Elisa Mancuso MD, PhD is a Senior Consultant in Haematology with a special interest in haemostasis. She obtained a post-degree in Clinical and Experimental Haematology and a PhD in Clinical Methodology. She worked as a Clinical Assistant at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan (Italy) from 2008 to 2020. Since May 2020 she has been Senior Consultant at the Center for Thrombosis and Haemorrhagic Diseases at IRCCS Humanitas Research Center in Rozzano, Milan (Italy). Dr Mancuso is involved in clinical research and has published several original articles in peer-reviewed journals such as The Lancet, Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is a member of the Editorial Board of the Journal of Thrombosis and Haemostasis and is a reviewer for several peer-reviewed journals in the field of Thrombosis and Haemostasis and is a member of several national and international scientific societies (AICE, SISET, ISTH, WFH, ASH, EAHAD). She has acted as Co-Chair of the Scientific and Standardization Subcommittee of ISTH (SSC-ISTH) on FVIII, FIX and rare bleeding disorders. Dr Mancuso has been involved as co-investigator in several clinical trials, and takes care of both children and adults with haemophilia with a specific scientific interest in inhibitors, chronic hepatitis C, optimisation of prophylaxis and novel therapies.
Bayer, Biomarin, Bioscience, Catalyst, CSL Behring, Novo Nordisk, Octopharma, Pfizer, Grifols, Kedrion, LFB, Roche, Sanofi, Sobi, Takeda, Spark Therapeutic and UniQure.
Learnings from clinical practice
Prof. Karin Fijnvandraat and Dr Maria Elisa Mancuso discuss their views on prophylaxis in children with haemophilia.